Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)
A legfontosabb adatok
- Ki végzi
- InnovHeart
- Hol
- Los Angeles, New York, Portland, Sacramento és Thousand Oaks (Egyesült Államok)Mind a 5 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 15 fő, tervezett
- Kezdés
- 2026. aug. 5.
- Várható befejezés
- 2032. szept.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Mitral Valve Replacement
- A regiszteradat frissítve
- 2026. augusztus 10.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 50 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years or older
- Symptomatic, moderate to severe or severe, functional or mixed, mitral regurgitation (≥ Grade 3+)
- NYHA functional Class ≥ II. If Class IV, patient must be ambulatory
- Ability to tolerate oral anticoagulation
- Ability to qualify for bailout surgery (which may include open heart surgery)
- High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team
- Willing and able to complete study-related assessments and questionnaires
Ki nem vehet részt
- Endocarditis in the 3 months prior to procedure date
- COPD on home oxygen therapy deemed too high risk for intubation
- Myocardial infarction during prior 30 days
- Stroke or TIA during prior 90 days
- Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed)
- Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment
- Prior surgical mechanical valve AVR
- Prior TAVI. -Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure
- CRT, CRT-D, IPG or ICD implanted in previous 30 days
- Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or IABP/mechanical circulatory support; CABG or PCI within previous 30 days
- Prior or planned heart transplantation (UNOS status 1)
- Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement
- Life expectancy <1 yr. due to noncardiac conditions
- Current admission with acute heart failure exacerbation
- Active systemic infection
- Severe pulmonary arterial hypertension (PAH), defined as PASP > 70mmHg
- Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states)
- Severe connective tissue disease under chronic immunosuppressive or cortisone therapy
- Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy; Procedural Exclusion Criteria
- Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy)
- Documented hypersensitivity to nickel or titanium; Cardiac Imaging Exclusion Criteria (evaluated by Core Labs)
- Chronic renal failure defined as eGFR < 30 mL/min/m2 or on renal replacement therapy
- Platelets < 90,000
- Purely degenerative (organic/primary) (i.e. intrinsic valve lesions) mitral regurgitation
- Dependency on inotropic agents or mechanical circulatory support
- Untreated clinically significant CAD
- Modified Rankin Scale ≥4 disability
- Refuses blood transfusions
- Participating in other investigational studies likely to confound the results or affect the study
- Unable or does not sign the study informed consent form
- Patients classified as "vulnerable patients"; Cardiovascular Exclusion Criteria
- Physical evidence of right-sided CHF:; Patients with ascites; Patients with anasarca (generalized edema / hydropsy)
- Contraindications to TEE imaging
- Left ventricular EF ≤ 30% by echocardiogram
- Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass
- Extensive mitral flail leaflets
- Evidence of new or untreated intracardiac thrombus, mass, or vegetation
- Severe right ventricular dysfunction
- Severe tricuspid regurgitation
- Hemodynamically significant inter-atrial shunt (ASD)
- Severe aortic regurgitation or aortic stenosis
- Anatomic ineligibility for SATURN Valve or SATURN TS procedure as determined by the Screening Committee
Helyszínek itt: Egyesült Államok
- Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Mitch GheorghiuToborzás még nem indult
- Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, Egyesült ÁllamokContact: Treena WilliamsRésztvevőt keres
- Oregon Health Science UniversityPortland, Egyesült ÁllamokContact: Amy KoskiToborzás még nem indult
- UC Davis HealthSacramento, Egyesült ÁllamokContact: Kaelyn Tuerner-LeeToborzás még nem indult
- Los Robles Regional Medical CenterThousand Oaks, Egyesült ÁllamokContact: Reas SolomonRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US).
A teljes eredeti leírásKevesebb
The purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.
Primary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.
A vizsgálat csoportja
- SATURN TMVR CohortA vizsgált kezelés
Saturn transseptal TMVR System implant
Kezelés: Mitral Valve Replacement
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-septal TMVR System in Patients With Severe, Symptomatic Mitral Regurgitation (Cassini-US)
- A regiszteradat frissítve
- 2026. augusztus 10.